Navaux

10 years of data in prostate cancer…you can’t rush the science…so we waited…hoping…believing…that one day…we could improve the lives of patients. Accepted publication!

Stay TUNED….Q1 2026!!!

https://www.linkedin.com/posts/don-e-fowler-72098812_early-cancer-diagnostic-testing-results-activity-7282818346712973313-ifa4?utm_source=share&utm_medium=member_desktop

Don E. Fowler on LinkedIn: **Early cancer diagnostic testing results from Navaux look very… **Early cancer diagnostic testing results from Navaux look very promising!** We've found new ways to detect tumor development in patients before most molecular…

🚀 Years Of Research At Navaux Begins To Redefine Hepsin's Role In Cancer Genesis 🚀

At Navaux, we’re on a mission to revolutionize cancer detection with our cutting-edge research in non-invasive early detection. We’re thrilled to share a major breakthrough in our work with serine proteases, particularly hepsin.
While many have explored hepsin before, our team has uncovered critical differences between full-length hepsin and circulating, activated hepsin—insights that had eluded others. This discovery is a significant step forward in understanding cancer biomarkers and improving early detection methods.
We’re proud to announce that we’ve completed epitope mapping and filed patents for our innovative findings related to hepsin. This advancement brings us closer to transforming how cancer is detected and treated, ultimately paving the way for better patient outcomes.
A huge thank you to our dedicated team for their hard work and perseverance. We’re excited about the future and the potential impact of our discoveries!
🔬💡 Stay tuned for more updates as we continue to advance the field of cancer research.
hashtag hashtag hashtag hashtag hashtag hashtag hashtag

We just went live with our new website! Please check out what we are doing in our cancer fight!

Navaux Early Cancer Detection Diagnostics

Navaux, Inc. adds Brent Staggs, M.D. to Advisory Board

Navaux, Inc. announced today, the addition of Brent Staggs to its Advisory Board. Dr. Staggs graduated Magna cm Laude from Ouachita Baptist University and received his Doctor of Medicine, from the University of Arkansas College of Medicine. After completing his residency in Pathology, he completed Fellowships in Hematopathology and Gastrointestinal Pathology at University of Arkansas for Medical Sciences. He has special training in Molecular Pathology, Pulmonary Pathology and Dermatopathology. Dr. Staggs is board certified in Anatomic, Clinical, and Hematology and is a Certified Medical Review Officer. In addition to being a well-respected guest lecturer throughout the country, he is well published in the field of cancer. Dr. Staggs maintains practice membership with Pathology Laboratories of Arkansas, P.A. who currently provide pathology services to Baptist Health throughout Arkansas. “Dr. Staggs brings a wealth of knowledge related to solid tumors in the clinical setting. This will provide Navaux with uncompromised direction as we pursue our mission of uncovering and treating cancer in its earliest stage.” – Don Fowler, CEO